Survival curve fitting using the Gompertz function: A methodology for conducting cost-effectiveness analyses on mortality data

Computer Methods and Programs in Biomedicine

Volumn 52, Issue 3, 1997, Pages 157-164

  Messori, A ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; CALCULATIONS; COMPUTER SOFTWARE; COST EFFECTIVENESS; FUNCTIONS; LEAST SQUARES APPROXIMATIONS; PARAMETER ESTIMATION; PATIENT TREATMENT; PHARMACODYNAMICS; STATISTICS;

GOMPERTZ FUNCTION; MATRIX HANDLING CALCULATIONS; MORTALITY DATA; PHARMACOECONOMIC METHODOLOGY; SURVIVAL CURVE FITTING;

CURVE FITTING;

ARTICLE; COMPUTER PROGRAM; MATHEMATICAL MODEL; MORTALITY; SURVIVAL;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; HUMANS; MORTALITY; SOFTWARE; STATISTICS; SURVIVAL ANALYSIS;

EID: 0031106774     PISSN: 01692607     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-2607(96)01788-9     Document Type: Article

References (14)

1. [1] D.B. Mark, M.A. Hlatky, R.M. Califf, et al., Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction, New Engl. J. Med. 332 (1995) 1418-1424.
2. [2] M. Gibaldi and D. Perrier, Pharmacokinetics (Marcel Dekker, New York, 1982).
3. [3] G. Varoli, Matematica Finanziaria (Patron, Bologna, 1990).
4. [4] E.T. Lee, Statistical Methods for Survival Data Analysis (Belmont, CA: Lifetime Learning, 1980).
5. [5] L. Sheiner and S.L. Beal, Some suggestions for measuring predictive performance, J. Pharmacokinet. Biopharm, 9 (1981) 503-512.
6. [6] A. Messori, C. Brignola, G. Trallori, et al., Effectiveness of 5-aminosalicylic acid (5-ASA) for maintaining remission in patients with Crohn's disease: a meta-analysis, Am. J. Gastroenterol. 89 (1994) 692-698.
7. [7] A. Messori, R. Rampazzo, G. Scroccaro, et al., Effectiveness of gabexate mesilate in acute pancreatitis: a meta-analysis. Dig. Dis. Sci. 40 (1995) 734-738.
8. [8] A. Messori, S. Trippoli and E. Tendi, G-CSF for the prophylaxis of neutropenic fever in patients with small-cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation, J. Clin. Pharm. Ther. 21 (1996) 57-63.
9. [9] M. Rinaldi, F. Bardelli, R. Rampazzo, P. Lusuriello and A. Messori, Effectiveness of immunoglobulins for the prevention of systemic infections - a meta-analysis of eight clinical studies in premature infants, Clin. Drug Invest. 10 (1995) 328-336.
10. [10] D.B. Mark, Economic analysis methods and end-points. In: Acute coronary care in the thrombolytic era, eds. R.M. Califf, D.B. Mark, G.S. Wagner, pp. 167-182 (St. Louis: Mosby, 1995).
11. [11] A. Messori, P. Becagli, S. Trippoli and E. Tendi, Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer, Eur. J. Clin. Pharmacol. 51 (1996) 111-116.
12. [12] A. Messori, L. Bonistalli, M. Costantini, G. Trallori and E. Tendi, Cost-effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer, J. Clin. Gastronterol. (1996) in press.
13. [13] R. Robinson, Cost-effectiveness analysis, BMJ 307 (1993) 793-795.
14. [14] D. Coyle, Statistical analysis in pharmacoeconomic studies - A review of current issues and standards, Pharmacoeconomics 6 (1996) 506-516.